Kepos Capital’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Kepos Capital’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-59,000	Closed	-$568K	–	613
2022 Q1	$568K	Sell	59,000 -416,000	-88%	-$3.73M	0.04%	215
2021 Q4	$4.71M	Buy	475,000 +250,000	+111%	+$2.49M	0.39%	111
2021 Q3	$2.23M	Buy	225,000 +96,502	+75%	+$946K	0.15%	252
2021 Q2	$1.26M	Buy	+128,498	New	+$1.25M	0.09%	253

Other funds holding GRNA

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return

CGC

Continental Grain Company New York $366M AUM 0.18% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

TCM

Tao Capital Management San Francisco, California $119M AUM 87.46% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kepos Capital's GRNA Position: Q2 2022 in Review

Kepos Capital sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q2 2022, closing a stake of 59,000 shares — an estimated $568K sold.

Kepos Capital first reported a position in GRNA in Q2 2021 and held it in 4 quarters. The position peaked at $4.71M in Q4 2021. 50 funds tracked by Wall St. Rank hold GRNA as of Q2 2022.

Kepos Capital reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q2 2022 after selling out during the quarter.
Kepos Capital sold 59,000 GreenLight Biosciences Holdings, PBC Common Stock shares in Q2 2022, an estimated $568K.
Kepos Capital first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q2 2021 and held it in 4 quarters.
Kepos Capital's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $4.71M in Q4 2021.
50 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q2 2022.

Based on Kepos Capital's 13F filing for Q2 2022, filed 12 Aug 2022.